Milestone Pharmaceuticals Closes $55 Million Series C Financing

Proceeds to Fund Etripamil Phase 3 Development and Pre-Launch Market Development MONTREAL, August 1, 2017 -- (Healthcare Sales & Marketing Network) -- Milestone Pharmaceuticals Montreal, Canada, Inc., a clinical stage cardiovascular company, today anno... Biopharmaceuticals, Venture Capital, Personnel Milestone Pharmaceuticals, etripamil, supra-ventricular tachycardia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news